FDA Statement: Case of Hemorrhagic Occlusive Retinal Vasculitis After Intraocular Injections of a Compounded TMV Formulation

FDA received an adverse event report on August 14, 2017, from a physician concerning a patient who was diagnosed postoperatively with bilateral hemorrhagic occlusive retinal vasculitis (HORV) after being administered injections of a compounded triamcinolone, moxifloxacin, and vancomycin (TMV) formulation in each eye at the conclusion of cataract surgery procedures that were done two weeks apart. The TMV formulation was compounded by Imprimis Pharmaceuticals, Inc., located in Ledgewood, New Jersey.

Source: ASCA/FDA MedWatch

0 replies

Leave a Comment

Leave a Reply

Your email address will not be published.